Skip to main navigation Skip to search Skip to main content

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

  • Deborah Suissa
  • , Marine Fidelle
  • , Ella Reich
  • , Thao-Nguyen Pham
  • , Simon Thomas
  • , Johannes R. Bjork
  • , Peng Liu
  • , Liwei Zhao
  • , Koji Kitaoka
  • , Eleonore Piard
  • , Isabelle Lebhar
  • , Ai-Ling Tian
  • , Cassandra Thelemaque
  • , Carolina Alves Costa Silva
  • , Eric Deutsch
  • , Yohann Loriot
  • , Nicola Segata
  • , Gianmarco Piccinno
  • , Geke A. P. Hospers
  • , Saman Maleki Vareki
  • Michael S. Silverman, John G. Lenehan, Veronique Bataille, David Boulate, Tatiana Kuznetsova, Rinse K. Weersma, Meriem Messaoudene, Sylvere Durand, Carlijn M. van der Aalst, Harry J. de Koning, Beatrice Schuler-Thurner, I. Jolanda M. de Vries, Edmond Rafie, Renee Maria Saliby, Marc Machaalani, Sebastian Haferkamp, Bastian Schilling, Serena Porcari, Chiara Ciccarese, Roberto Iacovelli, Chiara Cremolini, Toni K. Choueiri, Arielle Elkrief, Guido Kroemer, Lucie Heinzerling, Kenji Chamoto, Gianluca Ianiro, Bertrand Routy, Lisa Derosa, Nikos Paragios*, Laurence Zitvogel*
*Corresponding author for this work
  • Institut national de la santé et de la recherche médicale
  • University of Groningen
  • Sorbonne Université
  • Unicancer
  • Kyoto University
  • Fundação Oswaldo Cruz
  • Universidade Federal da Bahia
  • University of Trento
  • University of Western Ontario
  • University of London
  • Mount Vernon Cancer Centre
  • Aix-Marseille Université
  • Hopital Marie Lannelongue
  • KU Leuven
  • Université de Montréal
  • University of Erlangen Nuremberg
  • Radboud University Nijmegen
  • Harvard University
  • Yale University
  • University of Regensburg
  • Goethe University Frankfurt
  • Catholic University of the Sacred Heart
  • University of Pisa
  • Assistance publique – Hôpitaux de Paris
  • University of Munich Grosshadern
  • Universite Paris Saclay

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Immune-checkpoint inhibitors benefit a subset of patients with advanced cancer, and the metabolic determinants of response remain unclear. Here, using targeted metabolomics and metagenomics, we profiled 4,336 plasma samples from 1,714 patients across five tumor types and 16 cohorts spanning Europe and North America, longitudinally sampled during five immune-checkpoint inhibitor-based treatment modalities, including fecal microbiota transplantation. A multimodal machine-learning framework integrating 154 metabolites with clinical variables identified five metabolites, age, body mass index and renal function as predictors of 12-month progression-free survival. The model achieved areas under the curve of 0.88 in training and 0.73 in validation cohorts of 105 and 30 patients, respectively and generalized across seven external cohorts. Histidine was a favorable prognostic feature of survival, whereas long-chain fatty acids and succinate were negatively associated with outcome. Histidine supplementation enhanced antitumor immunity in mice. Histidine-rich diets improved progression-free survival in patients lacking dysbiotic microbiome signatures associated with histidine catabolism.
Original languageEnglish
Pages (from-to)2918-2932
Number of pages51
JournalNature Medicine
Volume32
Issue number8
DOIs
Publication statusPublished - Aug 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling'. Together they form a unique fingerprint.

Cite this